Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting

by | Jun 6, 2024 | Publications | 0 comments

Ann Hematol. 2024 Jun 6. doi: 10.1007/s00277-024-05835-4. Online ahead of print.

NO ABSTRACT

PMID:38839622 | DOI:10.1007/s00277-024-05835-4

Submit a Comment